Trial Profile
An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemirolast (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Cardoz; RSP Pharma
- 22 Apr 2014 New trial record